Company ProfilePremium

Arex Industries Limited

Company Profile Analysis

Ticker: 526851.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Arex Industries Limited - Company showcase

Year Founded & Workforce

1989

247 Employees

Arex Industries Limited logo

Arex Industries Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Arex Industries Limited Overview

Arex Industries is a promoter-controlled Indian micro-cap that designs and weaves branded identification labels: woven labels in satin and taffeta, plus printed labels. Its customers are apparel, home-textile and footwear manufacturers. Founded in 1989 by Dinesh Bilgi and now run jointly with his sons Neel and Chirag, it operates two Gujarat plants. The first is a computerised weaving unit at Chhatral near Ahmedabad. The second is a captive-style unit at Anjar, Kutch, built beside Welspun's home-textile campus under a 10-year agreement in which Welspun committed to take at least 75% of that plant's capacity. CARE describes Arex as one of the larger organised domestic players in a niche, fragmented segment dominated by unorganised producers. Revenue has held at about INR 45–54 crore for five years, EBITDA margins sit in the mid-teens, and capacity utilisation runs at 40–60%. The investment case therefore depends on whether the company can lift utilisation, grow its small but fast-rising export book, and convert a planned move into packaging materials into growth.


What the company does

Arex makes garment and textile identification labels: the woven or printed tags sewn into apparel, bed linen, towels and footwear to carry the brand name, size, care instructions and other trim information. CARE (June 2025 and July 2026) describes the core product as woven labels of satin and taffeta quality in white or black warp-base, made in shapes, sizes and colours specified by each customer, alongside a line of printed labels.

The company's legacy product page says it can supply about 414 million woven labels a year. The labels can be woven up to 500 mm wide in up to 12 colours, with coloured warp-bases available on custom orders. Edge options are ultrasonic cutting, hot-slit edges on broad looms, and soft edges on needle looms. Finishing options include end fold, centre fold, mitre fold, Manhattan fold, starching, special coatings, self-adhesive and thermo-adhesive backings, laser cutting, die cutting, filled-in labels and "comfort soft" finishes.

Company's own description

In BSE filings and its corporate profile, the company describes itself as a manufacturer and trader of woven and printed labels. It emphasises translating customer requirements into weaving patterns, a computerised plant using imported machinery, international quality standards, and reliable delivery against tight schedules. The FY2026 Integrated Annual Report's MD&A could not be accessed directly. Its key themes, as captured in secondary summaries, were softer domestic demand, sharply higher exports, rising employee costs, and an amendment to the Memorandum of Association adding packaging materials as a business object.

Independent characterisation

Arex is a business-to-business, made-to-order textile trim converter. Its economics follow from four features:

  1. Design-led, short-run manufacturing. Every order starts with design work (CAD artwork translated into weave patterns), sampling and approval. This creates mild switching costs once a brand's label is approved. It also means a long order-to-cash cycle and heavy inventory, because Arex keeps stocks of many coloured yarns so it can respond to any brand's palette. CARE reported inventory periods of 68 days in FY25 and 87 days in FY26.

  2. Low share of customer wallet, low pricing power. Labels are a tiny fraction of a garment's cost. Buyers are price-sensitive, and the unorganised sector caps price increases. CARE repeatedly notes that Arex has limited ability to pass on yarn price increases, which track cotton and crude oil.

  3. Capital intensity relative to revenue. Weaving looms (airjet, rapier and needle) and finishing lines carry a large fixed asset base. At 40–60% utilisation, fixed-asset turnover was only about 0.47x in FY26 and 0.49x in FY25 (CARE). Depreciation of about INR 4.1–4.4 crore a year consumes more than half of EBITDA.

  4. Anchor-customer dependence. The Anjar plant is effectively dedicated to Welspun under a minimum 75% offtake agreement. The top ten customers were 57% of operating income in FY25 and 60% in FY24 (CARE).

Revenue model

Revenue typeShareComment
Manufactured product sales (woven labels)Majority, exact split not publicly disclosedCore business. Billed per piece or per batch on job-specific pricing.
Manufactured product sales (printed labels)Minority, not publicly disclosedInstalled capacity 15,000 million pick metres (CARE)
Traded goods (labels / trims)—The company describes itself as "manufacturing & trading"
Services / subscription / licensingNilNo recurring service or licensing revenue
Power (wind)Captive. Not separately disclosed as revenue.Two windmills of 1.60 MW aggregate at Porbandar (CARE). Likely offsets grid power cost.

Value chain position

Arex sits between yarn suppliers (synthetic polyester and cotton tape/yarn) and garment, home-textile and footwear manufacturers. Those manufacturers in turn serve domestic and global brands and retailers. Label specifications are often set by the brand owner, while the purchase order is placed by the garment or home-textile maker. Arex's relationship is therefore usually with the converter, such as Welspun or the Tirupur knitwear exporters, rather than with the end brand.

Customer types and end-markets

End-marketEvidenceDemand character
Ready-made garments (domestic and export-oriented)CARE: demand arises mainly from apparel / RMGCyclical. Follows domestic consumption and Indian apparel exports.
Home textiles (towels, bed linen)CARE: home textiles a key segment; Welspun is the anchor customerStrongly linked to US retail demand. CARE noted the FY23–FY24 slowdown and recovery from Q4 FY24.
FootwearCARE: footwear is an additional end-marketSmaller share
Export customersExports INR 2.97 crore in FY26 vs INR 0.75 crore in FY25 (+311%)Nascent but growing

Financial Narrative

Sources: Screener.in (C-MOTS data compiled from BSE filings); CARE Ratings PRs of 27-Jun-2025 and 06-Jul-2026 (audited FY23–FY25, abridged FY26); FY26 audited results as summarised by ScanX (21-May-2026 and 24-Aug-2026); FinancialFilings.com (FY26 headline figures). "Derived" means computed by this analyst from disclosed figures. "Rounded" means Screener's whole-crore presentation.

Income statement (INR Cr)

Gross profit is not reported by the company in a comparable form (Ind AS presentation by nature of expense). Simply Wall St's TTM "gross profit" of INR 35.06 crore is revenue minus material cost. It is not comparable to a conventional gross margin and is excluded.

Margin profile (%)

Revenue growth: the four-year CAGR from FY2022 to FY2026 is −2.0% (derived). The five-year CAGR from FY2021 (INR 40.88 crore) to FY2026 is +4.0%, matching Screener's 3.96%. The ten-year sales CAGR is about 4% (Screener). Profit CAGR is −7% over ten years and +28% over five years, flattered by the FY2021 loss base.

Quarterly trend (INR Cr) — last 13 quarters

Source: Screener quarterly table (from BSE result PDFs). Q1 FY27 PBT includes the INR 9.54 crore keyman insurance maturity, classified as an exceptional item. Ordinary PBT for Q1 FY27 was INR 2.24 crore versus INR 0.34 crore in Q1 FY26 (ScanX; Business Standard).

Small discrepancies across sources:

  • Q4 FY26 revenue is INR 12.38 crore (Screener) versus INR 12.37 crore in the ScanX summary of the audited result. Some outlets show INR 12.43 crore total income.

  • One aggregator (IndMoney) reports Q1 FY27 "revenue" of INR 23.82 crore. This appears to add the exceptional gain to sales and conflicts with the filed figure of INR 14.28 crore.

  • One ScanX summary describes Q1 FY26 as a net loss of INR 24.69 lakh. It was a profit of INR 24.69 lakh.

  • A ScanX Q2 FY26 summary mislabels lakh figures as "crore".

Commentary on income statement trends. Arex has been range-bound. Revenue peaked at INR 53.75 crore in FY22, a post-COVID restocking year. It fell 16% in FY23 when US retailers destocked home textiles and Welspun-linked volumes slowed (CARE notes the global home-textile slowdown in FY23–FY24). It recovered to about INR 51 crore in FY24–FY25 and slipped 2.9% to INR 49.64 crore in FY26 on weaker domestic demand, partly offset by a fourfold rise in exports.

The more important trend is margin compression. EBITDA margin fell from 20.9% (FY22) to 14.6% (FY26). CARE attributes the FY25 and FY26 declines mainly to higher employee costs; Q3 FY26 employee expenses rose 18.9% YoY. Because depreciation (about INR 4.1–4.4 crore) and interest (about INR 1.0–1.3 crore) are largely fixed, each point of EBITDA margin moves PBT disproportionately. The 1.3-point margin fall in FY26 cut PBT by 48%.

FY25 earnings were also helped by unusually high other income of INR 0.69 crore against INR 0.06 crore in FY26, which exaggerates the FY26 decline.

Q1 FY27 is a genuine operating inflection as well as a one-off. Revenue rose 26.7% YoY and OPM recovered to 23.5%, the highest since Q3 FY24. One quarter does not establish a trend, but it is the first sign of the operating leverage the plant base allows if utilisation rises.

Balance sheet (INR Cr, as at 31 March)

The "total debt" row shows 0 for FY2022 because CARE's gearing figure for that year was not available in sources accessed. Use the Screener row (INR 23 crore) for FY22. Receivables are disclosed in sources accessed only for FY25 and FY26; zeros in earlier years mean "not available", not nil.

Cash and liquidity

Sources: ScanX summary of FY26 annual report; CARE PR 06-Jul-2026. FY25 non-current borrowings are derived as total debt minus current borrowings and are approximate. All term loans fall due in FY27, so they have been reclassified to current liabilities, which pushed the current ratio to 1.0x (CARE).

Working capital (current assets minus current liabilities) is not reported directly. CARE's current ratio of 1.0x implies working capital of about zero at FY26-end after the term-loan reclassification. Screener reports working-capital days of 30 (FY25) and −1 (FY26).

Commentary on the balance sheet. Total assets have shrunk from INR 68 crore (FY19 peak) to INR 45 crore (FY26) as the Anjar asset base depreciates and debt is repaid. Borrowings fell from about INR 35 crore (FY19) to about INR 10.5 crore (FY26).

The FY25 buyback of 3.6 lakh shares at INR 195 (about INR 7.02 crore, plus buyback tax) was paid from free reserves. It cut net worth from INR 31.61 crore to INR 25.67 crore. Gearing therefore rose from 0.33x to 0.48x, also helped by directors' unsecured loans. In FY26 gearing improved to 0.38x as those unsecured loans were withdrawn (CARE).

There is no goodwill: the company has never made an acquisition. Book value per share was about INR 77 at FY26-end (Screener), before the Q1 FY27 insurance gain of INR 8.81 crore after tax. That gain would add roughly INR 24 per share to book value, net of the INR 0.90 crore dividend paid after the September 2026 AGM.

Cash flow (INR Cr)

The FY26 dividend (INR 0.90 crore) falls in FY27 cash flows. The FY25 CFO figure has two versions: CARE gives INR 8.67 crore, while the ScanX summary of the audited cash-flow statement gives INR 8.905 crore. The difference is likely pre-tax versus post-tax operating cash flow.

Commentary on cash flow. Cash conversion is the company's best financial attribute. CFO exceeded reported operating profit in every one of the last five years (103–126%), because depreciation is large and working capital has been released (debtor days fell from 103 in FY21 to 50 in FY26). With maintenance capex of only about INR 1 crore a year between FY21 and FY25, free cash flow of INR 7–9 crore a year funded about INR 25 crore of debt reduction from FY19 to FY24 and the FY25 buyback. FY26 capex rose to INR 4.74 crore (CWIP INR 3 crore at year-end). This may relate to modernisation or the planned packaging line, but the purpose is not disclosed. It cut FCF to about INR 3 crore.

Ratio analysis

Zeros in the TD/GCA row (FY22–FY23) and the CARE operating-cycle row (FY22–FY23) mean "not disclosed in sources accessed". FY22 interest coverage is derived from Screener's rounded interest figure.

ROIC is not reported. As a proxy, after-tax ROCE was about 6–9% in FY24–FY26, using Screener ROCE and the reported tax rates.

Overall ratio commentary. Returns are below the cost of equity. ROE averaged 7.6–8% over three, five and ten years (Screener), against a cost of equity for an Indian micro-cap that is likely in the mid-teens. The driver is not leverage, which is modest and falling. It is low asset productivity: fixed-asset turnover of about 0.47x (CARE) because looms run at 40–60% utilisation. CARE's own upgrade triggers make the point. The company would need ROCE of at least 12% sustained, EBITDA margins above 20% and gearing below 0.30x to warrant a higher rating. Sustained ROCE below 5% or margins below 15% were downgrade triggers, and FY26 margins of 14.6% breached the latter. Interest coverage of about 7x and net debt/EBITDA of about 1.4x indicate low solvency risk.


7. SEGMENTAL AND GEOGRAPHIC REVENUE MAPPING

Segment × geography

There is one segment, so segment × geography collapses to the geographic split below. Country-level export revenue is not publicly disclosed.

Geographic revenue (INR Cr)

Sources: FY26 annual report as summarised by ScanX (exports INR 296.71 lakh vs INR 74.59 lakh). ScanX headlines the export increase as "+311%", which does not match these figures. The arithmetic gives +298%; the dossier uses the computed figure. Domestic revenue is derived. FY2024 export revenue is not available in sources accessed (Screener's "Export Revenue" field is behind a paywall).

Analysis. Arex is overwhelmingly a domestic supplier. Much of its "domestic" revenue, however, comes from Indian exporters (Welspun's home textiles and Tirupur knitwear), so it is indirectly exposed to US and EU retail demand. FY26 was the first year in which direct exports became meaningful. Domestic revenue fell 7.4% while direct exports rose fourfold to 6% of sales. Destination markets are not disclosed. The likely explanation is that Arex now ships labels directly to overseas garment makers (for example in Bangladesh or Sri Lanka) nominated by brands, but this is an inference and not confirmed by the company. The domestic decline is consistent with CARE's comment about softer demand in the garment-label sector. A breakdown between Welspun-linked and other domestic revenue is not disclosed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

53.7545.0251.0151.1449.64

Operating expenses (INR Cr; FY25–26 derived as revenue minus PBILDT)

42.5338.2041.9242.9942.38

EBITDA / PBILDT (INR Cr; FY22 Screener, FY23–26 CARE)

11.226.839.078.157.26

Other income (INR Cr)

0.040.230.090.690.06

Depreciation (INR Cr; FY22–23 rounded)

444.164.134.36

Finance costs (INR Cr; FY22–23 rounded)

221.331.091.04

Profit before tax (INR Cr; FY22–23 derived from PAT and tax rate)

4.681.013.703.671.92

Tax rate (%)

2131312823

Net profit / PAT (INR Cr; FY22 derived from EPS)

3.700.702.542.631.48

EPS basic and diluted (INR)

9.351.776.427.314.11

Dividend per share declared for the year (INR)

00002.50

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA margin (%)

20.915.217.815.914.6

PBT margin (%)

8.72.27.37.23.9

Net margin (%)

6.91.65.05.13.0

Dividend payout (%)

000061

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1FY24Q2FY24Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Sales (INR Cr)

11.6812.8013.0513.4812.9712.3413.2012.6411.2713.0112.9912.3814.28

Operating profit (INR Cr)

1.862.403.521.322.491.372.581.761.702.631.521.403.36

OPM (%)

15.9218.7526.979.7919.2011.1019.5513.9215.0820.2211.7011.3123.53

Other income incl. exceptional (INR Cr)

0.000.000.000.090.000.650.000.040.000.000.000.069.54

PBT (INR Cr)

0.390.942.120.251.230.861.230.350.351.280.200.1111.78

Net profit (INR Cr)

0.280.771.470.030.830.570.980.260.251.000.26-0.038.81

EPS (INR)

0.711.953.710.082.101.582.720.720.692.780.72-0.0824.48

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Equity share capital (INR Cr; derived from share count)

3.963.963.963.603.60

Net worth (INR Cr; FY22–23 rounded Screener, FY24–26 CARE)

282931.6125.6727.74

Total borrowings (INR Cr; Screener rounded)

2318101211

Total debt (INR Cr; CARE gearing × net worth, FY23–26)

017.710.412.310.5

Other liabilities (INR Cr; rounded)

76897

Total assets (INR Cr; FY25–26 audited)

58535046.6244.97

Net fixed assets (INR Cr; rounded)

3633302725

Capital work-in-progress (INR Cr; rounded)

00013

Other assets incl. inventory and receivables (INR Cr; rounded)

2219201917

Trade receivables (INR Cr)

0008.076.83

Goodwill and intangibles (INR Cr)

00000

Balance Sheet and Financial Ratios (x)

MetricFY2025FY2026

Cash and cash equivalents (INR Cr)

0.050.11

Current borrowings (INR Cr)

7.0910.60

Non-current borrowings (INR Cr)

5.20

Net debt (INR Cr; derived)

12.2510.4

Current ratio (x; CARE)

1.311.00

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Cash from operations (INR Cr; FY22–23 rounded, FY24–26 CARE)

1089.488.677.58

Cash from investing (INR Cr; FY26 audited)

-1-1-1-1-4.74

Cash from financing (INR Cr; rounded)

-10-7-9-8-3

Free cash flow (INR Cr; Screener)

97873

Share buyback (INR Cr; derived)

0007.020

Dividends paid (INR Cr)

00000

CFO / operating profit (%)

103116106126119

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROCE (%; Screener)

13611128

ROE (%; derived, PAT / average net worth)

14.02.58.49.25.5

ROA (%; derived, PAT / average total assets)

6.11.34.95.43.2

Debt / equity (x; FY22 derived, FY23–26 CARE)

0.820.610.330.480.38

Net debt / EBITDA (x; derived)

2.02.61.151.511.43

Interest coverage, PBILDT / interest (x; FY23–26 CARE)

5.63.766.837.456.98

Total debt / gross cash accruals (x; CARE)

001.451.871.99

Asset turnover (x; derived, revenue / average total assets)

0.890.810.991.061.08

Debtor days (Screener)

6466685850

Inventory days (Screener, COGS basis)

229235192195197

Payable days (Screener)

92839411481

Cash conversion cycle (days; Screener)

201218166139166

Operating cycle (days; CARE basis)

001059398

Income Statement and Margin Analysis (%) (FY2025–FY2026)

RegionFY2025FY2026

Domestic India revenue (INR Cr; derived)

50.4046.67

Export revenue (INR Cr)

0.752.97

Total revenue from operations (INR Cr)

51.1449.64

Export share of revenue (%)

1.56.0

Growth metric

FY2026 YoY %

—

Domestic revenue growth

-7.4—

Export revenue growth

297.7—

Total revenue growth

-2.9—

Valuation Snapshot

MetricValueSource

Last price

INR 128.50 (ScanX, accessed 19-Oct-2026); INR 127.00 (Screener close 25-Sep-2026)

ScanX; Screener

52-week high / date

INR 165.70 / 1-Sep-2025

Business Standard

52-week low / date

INR 95.50 / 9-Apr-2026

Business Standard

All-time high / date

INR 314.70 / 20-Oct-2022

Business Standard

All-time low / date

INR 1.75 / 1-Feb-1999

Business Standard

6-month return

+18.4% (ScanX, Oct-2026)

ScanX

Metric

1Y

3Y CAGR

Stock price return (%; Screener, Sep-2026)

-183

Valuation Snapshot by Multiple

MultipleValueBasis

P/E, reported TTM

4.6x

TTM PAT INR 10.04 crore including the exceptional gain (ScanX shows 4.41x)

P/E, normalised TTM

About 15.9x

TTM PAT excluding the INR 9.54 crore exceptional gain (taxed at 25.3%) ≈ INR 2.91 crore; EPS about INR 8.1. Screener shows 15.2x.

P/E, FY26

31.3x

FY26 EPS INR 4.11

P/B

1.67x

FY26 net worth INR 27.74 crore; about 1.3x on post-Q1 FY27 book (estimated)

EV / EBITDA, FY26

7.8x

EV ≈ INR 56.7 crore (market cap 46.3 + net debt 10.4) / EBITDA 7.26

EV / EBITDA, TTM

6.4x

TTM operating profit INR 8.91 crore

EV / Sales, TTM

1.08x

TTM revenue INR 52.66 crore

Dividend yield

1.95%

INR 2.50 / INR 128.50

Dividend History

Fiscal yearDividend payout (%; Screener)Dividend per share (INR)

FY2015

13

Not disclosed in sources accessed

FY2016

41—

FY2017

25—

FY2018

23—

FY2019

31

2.00 (20%, ex-date 6-Sep-2019)

FY2020–FY2025

00

FY2026

61

2.50 (25%; record date 16-Sep-2026; outlay INR 89.97 lakh)

“—” = not publicly disclosed.

Capital Programmes

ProgrammeSizePriceRecord dateStatus

2024 tender-offer buyback

Up to 3,60,000 shares (about 9.1% of pre-buyback equity)

INR 195

7-Sep-2024

Completed; extinguished by 7-Oct-2024; about INR 7.02 crore

Credit Ratings

AgencyRatingOutlookDateStatus

CARE Ratings (CareEdge)

CARE BBB (long-term) / CARE A3+ (short-term)

Stable

6-Jul-2026

Reaffirmed and withdrawn at the company's request

Moody's / S&P / Fitch

Not rated

———

Capital Instruments

InstrumentAmount (INR Cr)MaturityStatus

Term loan 1

0—

Fully repaid; No Dues Certificate received (CARE, Jul-2026)

Term loan 2

Not disclosed (part of current borrowings)

March 2027

All outstanding term loans classified as current maturities in FY26 (CARE)

Cash credit / working capital

Part of current borrowings of INR 10.60 crore (FY26)

Revolving

CARE-rated limit INR 5.50 crore (Jun-2025)

Directors' unsecured loans

Withdrawn in FY26 (CARE)

——

Timing Details

TimingCatalyst / monitorableWhat to watch

26 Oct 2026

Q2 / H1 FY27 results

Whether revenue growth (+26.7% in Q1) and OPM above 20% persist; use of the INR 9.54 crore insurance proceeds; net debt at 30-Sep-2026

Jan 2027

Q3 FY27 results

Employee-cost trend; export run-rate

Mar 2027

Final term-loan maturity

Debt-free status

FY27

Packaging-materials launch

Any capex, plant or first revenue disclosure

May 2027

FY27 audited results and dividend

Dividend sustainability; payout policy

Ongoing

Welspun agreement

Any renewal or extension announcement before the roughly 2028 expiry

Ongoing

Promoter pledge (SAST disclosures)

Release or increase of pledged shares

Ongoing

US–India trade policy

Effect on home-textile and garment-export customers

Executive Leadership

Board of Directors

NameTitleTenure / statusBackgroundAge / birth yearDIN

Dinesh Apparao Bilgi

Managing Director and CFO; founder promoter

Founder (1989). Reappointed as MD effective 1 Aug 2026 (36th AGM).

More than 30 years in woven-label manufacturing. Runs day-to-day operations (CARE). Described as a "technocrat" with weaving expertise.

Born 1952 (about 74)

00,096,099

Neel Dinesh Bilgi

Managing Director (Sales and Marketing); promoter

Reappointed effective 1 Aug 2026

Son of the founder. More than 15 years of industry experience (CARE). Signs most BSE filings.

Born 1978 (about 48)

00,096,180

Chirag Dinesh Bilgi

Managing Director (Production and Technical); promoter

Reappointed effective 1 Aug 2026

Son of the founder. More than 15 years of industry experience (CARE).

Born 1983 (about 43)

02,094,970

Kairavi N. Bilgi

Company Secretary and Compliance Officer (KMP)

Since 1 Sep 2015

Promoter family member (same surname, "N." initial; relationship not formally disclosed in sources accessed)

——

Pragnesh K. Shah

Director (non-independent)

Retired by rotation and reappointed at 37th AGM (23-Sep-2026)

Classification conflicts across sources: one lists him as "Executive Director", others as non-executive. Retirement by rotation confirms he is non-independent.

——

Laxman C. Tilani

Non-executive director (non-independent)

Retired by rotation and reappointed at 37th AGM

———

Aviv J. Divekar

Non-executive Independent Director

Second and final five-year term, 1 Sep 2026 to 31 Aug 2031 (approved at 37th AGM)

———

Manoj Shah

Non-executive director (per Enrichmoney listing)

————

“—” = not publicly disclosed.

Governance Overview

AttributeAssessment

Chair / CEO separation

No CEO title is used. Three promoter family members are joint Managing Directors and the founder also holds the CFO role. Who chairs the board is not disclosed in sources accessed.

Executive concentration

Three of the roughly six or seven directors are promoter executives from one family. The CFO function sits with the founder MD rather than an independent finance professional.

Independence

At least one independent director (Aviv Divekar) is confirmed. The full count of independent directors required under SEBI LODR Reg. The FY26 ASCR reports no non-compliance, which implies the minimum composition was met.

Committees

Audit Committee confirmed to have pre-approved all related-party transactions (ASCR FY26). Composition of the Nomination & Remuneration and Stakeholder Relationship Committees is not disclosed in sources accessed.

Board evaluation

Performance evaluation of the board, independent directors and committees was conducted (ASCR FY26).

Regulatory record

No actions by SEBI or BSE against the company, promoters or directors in FY26 (ASCR FY26).

Succession

The second-generation MDs (aged about 43 and 48) are already in place, which reduces key-person risk around the 74-year-old founder. The maturity of a keyman insurance policy in Q1 FY27 (INR 9.54 crore) shows the company has insured that risk.

Board & Management Changes

DateChange

13 Aug 2025

Board proposes reappointment of all three MDs (Dinesh, Neel and Chirag Bilgi)

29 Sep 2025

36th AGM approves MD reappointments effective 1 Aug 2026

29 Jul 2026

Board recommends second term for Independent Director Aviv Divekar

23 Sep 2026

37th AGM approves Divekar's reappointment and the rotational reappointment of P.K. Shah and L.C. Tilani

Shareholding Trend

Holder categoryJun-2024Jun-2025Jun-2026

Promoters and promoter group (%)

70.5370.6070.60

Public (%)

29.4629.3829.39

DIIs (%)

000

FIIs (%)

000

Number of shareholders

2,3812,4082,181

Governance Timeline

DateInitiativeDetailQuantified targets

Aug–Sep 2024

Share buyback (tender offer)

Up to 3.6 lakh shares at INR 195; about INR 7.02 crore

Completed Oct 2024

13 Aug 2025

Business expansion into packaging materials

Board approved alteration of the MoA objects clause, ratified at 36th AGM

Capex, timeline, revenue targets not disclosed

FY2026

Capex programme

INR 4.74 crore invested in property, plant and equipment; CWIP about INR 3 crore at FY26-end

Purpose not disclosed

FY2026

Export push

Exports up about four times to INR 2.97 crore

No target disclosed

FY2026–Q1 FY27

Deleveraging

Non-current borrowings fully repaid; one term-loan lender issued a No Dues Certificate; all remaining term loans due in FY27

Debt-free target not stated

6 Jul 2026

Credit rating withdrawal

Requested by the company after lenders issued NOCs

Signals reduced reliance on rated bank debt

May–Sep 2026

Dividend resumption

INR 2.50 per share for FY26 (25% of face value)

No formal dividend policy disclosed

Competitive Landscape

Key Competitors

#CompetitorTierHome baseRelevance to Arex
1

Avery Dennison (Solutions Group, formerly RBIS / Paxar)

Global

USA (NYSE: AVY)

Largest global apparel label and RFID supplier; Indian operations serve export garment makers

2

CCL Industries (CCL Design / Checkpoint Systems apparel labelling)

Global

Canada (TSX: CCL.B)

Woven and printed labels and RFID via Checkpoint (acquired 2016)

3

SML Group

Global

Hong Kong (private)

Woven and printed labels and RFID; India manufacturing

4

r-pac International

Global

USA (private)

Trims and labels for brands

5

Finotex

Global

Colombia / USA (private)

Woven labels and trims; Asian plants

6

Trimco International

Global

Hong Kong (private)

Labels and trims

7

ITL Group

Global

Hong Kong / UK (private)

Labels and RFID

8

Nilorn Group

Global / regional

Sweden (Nasdaq Stockholm)

Woven labels and branding; production in South Asia

9

Organised Indian woven-label converters (Tirupur / Bangalore / NCR clusters)

Domestic organised

India (mostly unlisted)

Direct competitors for domestic garment makers

10

Unorganised local weavers and printers

Domestic unorganised

India

Set the price floor; limit pass-through (CARE)

11

Customers' in-house label units (vertical integration)

Captive

India

Large home-textile and garment groups can insource labels

Peer Comparison FY2026

MetricArex Industries (FY26)Avery Dennison (FY24)CCL Industries (FY24)SML Group

Revenue

INR 49.64 crore (about USD 5.8 million)

About USD 8.8 billion (group)

About CAD 7.2 billion (group)

—

Revenue growth

−2.9%———

EBITDA margin

14.6%———

RFID / digital ID capability

None disclosed

Yes (market leader)

Yes (Checkpoint)

Yes

Footprint

2 plants, India only

Global

Global

Global

“—” = not publicly disclosed.

Recent Developments

ScanX gave the 37th AGM date as 25 September 2026 in one headline. BSE filings confirm 23 September 2026.

Company Snapshot

$5.7M

Revenue

247

Employees

1989

Founded

District Gandhinagar, India

Headquarters

SWOT Analysis

Strengths

  • Strong cash conversion: CFO / operating profit of 103–126% in each of FY22–FY26; CFO INR 7.6–10 crore a year (Screener; CARE)
  • Deleveraged balance sheet: Borrowings down from about INR 35 crore (FY19) to about INR 10.5 crore (FY26); gearing 0.38x; non-current debt fully repaid by FY26 (CARE; ScanX)
  • Contractual anchor demand: Welspun's 10-year minimum 75% offtake of Anjar capacity, with fixed-cost reimbursement if capacity is idle (CARE 2025)
  • Long operating record and an established client base: More than 30 years; one of the larger organised players; Welspun (CARE AA) among the clients (CARE 2026)
  • Spare capacity for growth without capex: Installed 27,015 million pick metres of woven and 15,000 million pick metres of printed capacity, utilised at only 40–60% (CARE)
  • Shareholder-friendly capital return: INR 7.02 crore buyback (Sep 2024, about 13% of then market cap) and INR 2.50 dividend for FY26 at 61% payout
  • Key-person risk funded: Keyman insurance matured for INR 9.54 crore in Q1 FY27 (ScanX)
  • Clean regulatory record: FY26 ASCR shows no deviations and no SEBI or BSE actions

Weaknesses

  • Stagnant, sub-scale revenue: Five-year sales CAGR of 3.96%; FY26 revenue INR 49.64 crore, below FY22's INR 53.75 crore (Screener)
  • Low returns on capital: Three-year average ROE 7.63%; FY26 ROCE about 8%; fixed-asset turnover 0.47x (Screener; CARE)
  • Margin erosion: EBITDA margin down from 20.9% (FY22) to 14.6% (FY26), below CARE's 15% negative-sensitivity threshold
  • Customer concentration: Top-10 customers 57% of revenue (FY25), 60% (FY24); high single-customer dependence at Anjar (CARE)
  • Long working-capital cycle: Operating cycle about 98 days (CARE FY26); inventory 87 days and rising
  • Very limited disclosure: No investor presentations, calls or guidance; product mix, export markets and R&D undisclosed; FY26 OCI clerical error needed correction (Jul 2026)
  • Concentrated governance: Three promoter family MDs; founder is also CFO; promoter-family Company Secretary
  • Illiquid stock: Trading volumes in tens to hundreds of shares on many days (e.g., 84 shares on 30 Jul 2026); not on NSE

Opportunities

  • Operating leverage from utilisation: Q1 FY27 revenue +26.7% lifted OPM to 23.5% and ordinary PBT about 6.6 times YoY
  • Export growth: Exports up about four times to INR 2.97 crore (6% of sales) in FY26
  • Packaging-materials diversification: MoA amended (AGM 29-Sep-2025); adjacent converting know-how
  • Use of insurance proceeds: INR 9.54 crore inflow equals about 90% of FY26 debt; could make the company debt-free or fund packaging capex
  • India apparel-export tailwinds: New trade agreements and "China-plus-one" sourcing could raise Indian garment exports and label demand (macro, not quantified)
  • Value-added label technologies: RFID, recycled-yarn and traceability labels are high-growth categories in which Arex has no current presence

Threats

  • Welspun agreement renewal: About three years remaining as of Jul 2026 (CARE); renewal terms unknown
  • Raw-material volatility: Yarn prices track cotton and crude; limited pass-through (CARE)
  • Wage inflation: Employee costs +18.9% YoY in Q3 FY26
  • Unorganised and global competition: Fragmented industry with intense competition (CARE); global majors bundle RFID
  • Trade-policy shocks for Indian textile exporters: US tariff actions affecting India's apparel and home-textile exporters (macro)
  • Loss of rating visibility: CARE rating withdrawn in Jul 2026; lenders and investors lose an independent monitor

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 Apr 2025Market cap about INR 54.8 crore at INR 152.30 (Simply Wall St)Reference valuation point
28 May 2025FY25 audited results: revenue INR 51.14 crore, PAT INR 2.63 croreFlat revenue; PAT +4%
27 Jun 2025CARE reaffirms BBB; Stable / A3+ on INR 10.75 crore of facilities; term loan cut to INR 5.25 croreConfirms moderate credit profile; top-10 customer concentration disclosed at 57%
Jul 2025Quarterly Reg. 74(5) and investor-grievance compliancesRoutine
13 Aug 2025Q1 FY26 results: revenue INR 11.27 crore (−13% YoY), PAT INR 0.25 crore (−70%)Weakest quarter in two years
13 Aug 2025Board approves reappointment of three MDs and expansion into packaging materials; AGM set for 29 Sep 2025Strategic diversification signal
1 Sep 202552-week high of INR 165.70Peak of the trailing period
29 Sep 202536th AGM: eight resolutions passed, objects clause altered, MDs reappointed effective 1 Aug 2026Governance continuity; packaging mandate secured
29 Sep 2025Trading window closed from 1 Oct 2025 until 48 hours after Q2 resultsRoutine
30 Oct 2025Board meeting notice for 12 Nov 2025 (H1 results)Routine
12–13 Nov 2025Q2 FY26 results: revenue INR 13.01 crore (+5.4% YoY), PAT INR 1.00 crore (+75%), OPM 20.2%Recovery quarter; lower material costs
Sep 2025Net debt INR 10.51 crore (Zerodha / Tijori)Continued deleveraging
22 Dec 2025Share price INR 139.95; 3-year return +20.65% (Business Standard)Market data point
27 Jan 2026Q3 FY26 results: revenue INR 12.99 crore (−1.6%), PAT INR 0.26 crore (−73%); employee costs +18.9%Margin squeeze from labour costs
10 Apr 2026Reg. 74(5) certificate for Q4 FY26 (MUFG Intime)Routine
9 Apr 202652-week low of INR 95.50Trough; about 42% below 52-week high
21 May 2026FY26 audited results: revenue INR 49.64 crore (−2.9%), PAT INR 1.48 crore (−44%); Q4 net loss INR 0.03 crore; INR 2.50 dividend recommendedWeak year; first dividend since FY19
29 May 2026Annual Secretarial Compliance Report FY26: no deviations, no regulatory actionsClean compliance
6 Jul 2026CARE reaffirms BBB; Stable / A3+ and withdraws at company request; one term loan fully repaidExit from the rated-debt framework
29 Jul 2026Q1 FY27 results: revenue INR 14.28 crore (+26.7%), ordinary PBT INR 2.24 crore (vs 0.34 crore); exceptional gain INR 9.54 crore (keyman insurance maturity); PAT INR 8.81 crore; EPS INR 24.48Strongest operating quarter since Q3 FY24 plus a large one-off cash inflow
29 Jul 2026Clerical error in FY26 OCI line rectified (auditor-confirmed; FY26 total comprehensive income corrected to INR 1.37 crore; no change to PAT or revenue)Minor disclosure-quality issue
29 Jul 2026Record date set at 16 Sep 2026; book closure 17–23 Sep 2026Corporate action
29 Jul 2026Board recommends second five-year term for Independent Director Aviv Divekar (to 31 Aug 2031)Board continuity
1 Aug 2026MD reappointments take effectLeadership continuity
24 Aug 2026FY2025-26 Integrated Annual Report and 37th AGM notice filedPrimary disclosure document
27 Aug 2026Newspaper publication of AGM notice and IEPF transfer notice for unclaimed dividends/sharesRoutine; unclaimed shares to IEPF
23 Sep 202637th AGM: all resolutions passed (about 99.99% in favour); INR 2.50 dividend approvedShareholder approval
29 Sep 2026Trading window closure for Q2 FY27Routine
8 Oct 2026Reg. 74(5) certificate for Q2 FY27Routine
16 Oct 2026Board meeting called for 26 Oct 2026 to approve Q2 / H1 FY27 resultsNext catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Income Statement

3 charts
Income Statement (FY2022–FY2026): Revenue from operations fell from INR 537.5 Mn in FY2022 to INR 496.4 Mn in FY2026.
Arex Industries Limited — Income Statement (FY2022–FY2026)
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations537.5450.2510.1511.4496.4
Operating expenses (INR Cr; FY25–26 as revenue minus PBILDT)425.3382419.2429.9423.8
EBITDA / PBILDT112.268.390.781.572.6
Other income0.42.30.96.90.6
Depreciation404041.641.343.6
Finance costs202013.310.910.4
Net profit / PAT37725.426.314.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.